Medtronic News

Ashton is the managing partner of Centaur Capital Partners and manages the investments for the Centaur Value Fund.

After serving two years as the chief financial officer of New Hampshire-based Salient Surgical Technologies, Richard Altieri will now take the financial reigns of another medical technology business, this time for a company in Massachusetts.

Citigroup lowers its price target on Medtronic to $48, up $3, while reiterating its Buy rating as it trims estimates on the company, reflecting the belief that the med tech mart experienced a difficult January.

Employers are moving beyond "trash and trinkets" to more powerful financial incentives for employees to complete health risk assessments and take other steps to spot medical problems and to improve their health.

In an earlier article here , I presented a bullish case on InVivo Therapeutics , a development-stage medical device company with a core focus in treating spinal cord injury .

Citigroup upped their price target on shares of Medtronic from $45.00 to $48.00 in a research note issued on Friday.

Consistent with its commitment to developing better treatments for peripheral arterial disease , Medtronic Inc.

Boston Scientific Corporation A posted lower net income in the fourth quarter compared with a year-earlier period.

Physio-Control, the world's leading provider of emergency medical response technology for use in the intervention and treatment of sudden cardiac arrest and other medical emergencies, today announced the completion of the sale of the company to an affiliate of Bain Capital, a leading global private investment firm.

St. Jude Medical Inc., maker of devices to treat heart conditions, is betting on new technologies this year to overcome weak demand for older medical products, Chief Executive Officer Daniel Starks said.

Leading medical device player Medtronic recently came out with the results of two studies conducted on the company's CoreValve System delivered through the direct aortic implantation approach.

The seemingly never-ending road to recovery just got a little longer for Boston Scientific .

Medtronic, Inc. today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the implementation of evidence-based treatment guidelines among chronic heart failure patients post-hospital discharge.

Like others in the orthopedic devices industry, Zimmer Holdings Inc. has followed the agreement's progress.

Boston Scientific Corp . will unveil its latest earnings on Thursday, February 2, 2012.

Medical device makers will double how much they pay U.S. regulators to get their products reviewed over the next five years, to $595 million, in a deal designed to secure faster and more predictable evaluations, say two people with knowledge of the talks.

Bain Capital A has completed its $487 million acquisition ofA Physio-Control , a Redmond, Wash.based provider of emergency medical response technology, fromA Medtronic Inc.

Medtronic, Inc. today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve System delivered through the direct aortic implantation approach.

The deal, valued at $487 million, was announced in November, nine months after Minneapolis-based medical device giant Medtronic said it planned to divest the maker of emergency-response equipment such as defibrillators.

Medtronic was upgraded by research analysts at Wells Fargo & Co. from a "market perform" rating to an "outperform" rating in a report issued on Monday.